NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

LivaNova PLC (LIVN) Stock Analysis

LivaNova PLC (LIVN) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

LIVN

$81.92

+$0.72 (+0.89%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LIVN with… →

LIVN Key Statistics

As of Sep 4, 2026
Trading
Open
$80.67
Previous Close
$81.20
Day's Range
80.39–82.22
52-Week Range
48.82–85.76
Volume
334.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.87
Valuation
Market Cap
$4.50B
P/E Ratio
23.95
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
17.52
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.93
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.06
EPS (ttm)Profit attributable to each share over the last twelve months.
3.42
Financials (FY)
Revenue (FY)
$1.39B+10.74%
Net Income (FY)
−$242.47M−483.45%
Profit marginThe share of revenue left as profit after all costs and taxes.
12.81%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
54.93M
1-Year Return
+40.88%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
705.94K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LIVN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+33.14%
2025+32.87%
2024−10.49%
2023−6.84%
2022−36.47%
2021+32.05%
2020−12.22%
2019−17.54%
2018+14.45%
2017+77.72%
2016 (partial year)−25.67%

As of September 4, 2026.

LIVN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.39B−$242.47M−17.5%
2024$1.25B$63.23M5.0%
2023$1.15B$17.55M1.5%
2022$1.02B−$86.25M−8.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.39B$939.87M$199.39M−$242.47M−17.5%
2024$1.25B$853.48M$129.05M$63.23M5.0%
2023$1.15B$755.82M$21.48M$17.55M1.5%
2022$1.02B$707.23M$52.64M−$86.25M−8.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LIVN Valuation vs Medical Devices Median

Median of 151 stocks
MetricLIVNMedical Devices medianvs median
P/E23.9526.8011% below
P/S ratio3.062.983% above
Profit margin12.81%−1.69%14.5 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

LivaNova PLC (LIVN) is capitalised at $4.50B on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 3,300 employees.

LIVN last closed at $81.92 on September 4, 2026. That is +$0.72 (+0.89%) against the previous close. Over the past 52 weeks the price has ranged from $48.82 to $85.76. The latest close sits 67.8% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.39B. Against the prior fiscal year total of $1.25B, that is a change of +10.74%. The same year closed with a net loss of $242.47M. Profit margin runs at 12.81%. That is 14.5 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to 3.42.

Across the 4 fiscal years on file, revenue moves from $1.02B in 2022 to $1.39B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 23.95. That is 10.63% below the Medical Devices median of 26.8. On forward earnings the ratio is 17.52. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.93. The price-to-sales ratio is 3.06. On price-to-sales that is 2.76% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 0.87. Annualized volatility over the trailing 10 years is 40.38%. The trailing one-year price return is +40.88%. Measured over 10 years, that is +3.00% a year compounded.

Growth & Income

The record shows no dividend for LIVN.

Across the complete calendar years on file, 2017 returned +77.72% and 2022 returned −36.47%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the price is +33.14% year to date.

Peer Comparison

LivaNova PLC (LIVN) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
LivaNova PLC LIVN $4.50B 23.9
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. LivaNova PLC trades at a P/E of 23.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About LivaNova PLC

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.

Visit website →